Table 2.

Clinical trials for the palliative cytostatic chemotherapy of BTC specifically including GBC patients.

NCTN	Phase	Condition	Study Size	Substance	Results	Reference
NCT00660140	II	BTC + GBC	49	gemcitabine + carboplatin	PFS 7.8 months, OS 10.6 months	[77]
Not applicable	II	GBC	20	gemcitabine + carboplatin	ORR 36.7%, PFS 33.8 weeks	[78]
NCT00009893	II	BTC + GBC	42	gemcitabine + 5FU + leucovorin	PFS 4.6 months, OS 9.7 months	[79]
NCT00003276	II	BTC + GBC	39	irinotecan	ORR 8%	[80]
NCT00033540	II	BTC + GBC	57	gemcitabine + capecitabin	ORR 25%, OS 7 months	[81]
NCT00059865	II	BTC + GBC	63	gemcitabine + pemetrexed	No benefit of combined regimen compared to gemcitabine	[82]
NCT00075504	II	BTC + GBC	33	triapine + gemcitabine	ORR 9%; no benefit with triapine	[83]